Search Result

Results for "

Mcl-1 protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (1) Apoptosis (22) Autophagy (4) Bacterial (1) Bcl-2 Family (22) Btk (1) c-Myc (4) Calcium Channel (1) Caspase (3) CDK (6) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) FLT3 (1) Fungal (2) HIV (1) JAK (2) JNK (1) Ligands for Target Protein for PROTAC (1) Molecular Glues (1) Necroptosis (1) NF-κB (2) Notch (1) P-glycoprotein (1) p38 MAPK (1) PIN1 (1) PROTACs (2) Reactive Oxygen Species (ROS) (1) ROS Kinase (1) Ser/Thr Kinase (1) STAT (4) Survivin (3) Virus Protease (1) Wnt (1)
By Research Areas:	Cancer (34) Infection (5) Inflammation/Immunology (1) Neurological Disease (2)

By Targets:

Akt (1)

Antibiotic (1)

Apoptosis (22)

Autophagy (4)

Bacterial (1)

Bcl-2 Family (22)

Btk (1)

c-Myc (4)

Calcium Channel (1)

Caspase (3)

CDK (6)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

FLT3 (1)

Fungal (2)

HIV (1)

JAK (2)

JNK (1)

Ligands for Target Protein for PROTAC (1)

Molecular Glues (1)

Necroptosis (1)

NF-κB (2)

Notch (1)

P-glycoprotein (1)

p38 MAPK (1)

PIN1 (1)

PROTACs (2)

Reactive Oxygen Species (ROS) (1)

ROS Kinase (1)

Ser/Thr Kinase (1)

STAT (4)

Survivin (3)

Virus Protease (1)

Wnt (1)

By Research Areas:

Cancer (34)

Infection (5)

Inflammation/Immunology (1)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155472

Mcl-1 inhibitor 17	Bcl-2 Family	Cancer
Mcl-1 inhibitor 17 is a Mcl-1 protein inhibitor. Mcl-1 inhibitor 17 can be used for the research of cancer and other diseases .

HY-132307

Mcl-1 inhibitor 6	Bcl-2 Family Apoptosis	Cancer
Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a K_d of 0.23 nM and a K_i of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, K_d>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent .

HY-162858

BRD-810	Caspase	Cancer
BRD-810 is a highly selective *MCL1* inhibitor. BRD-810 can bind to the BH3 groove of MCL1 and block the sequestration of pro-apoptotic proteins, quickly inducing caspase activation in MCL1-dependent cell lines. BRD-810 shows anti-tumor activity in models of blood cancers and solid tumors .

HY-112591

NSC260594	Apoptosis HIV Wnt Bcl-2 Family	Cancer
NSC260594 induces Apoptosis. NSC260594 binds the shallow groove of the *Mcl-1* protein, and inhibits Mcl-1 expression through down-regulation of Wnt signaling proteins. NSC260594 can also recognize G9-G10-A11-G12 RNA tetraloop of HIV and prevent the binding of the Gag protein within the 5’-UTR. NSC260594 inhibits tumor growth, and can be used for research of Triple-negative breast cancers (TNBCs) .

HY-170763B

(-)-Mcl-1 inhibitor 22	Bcl-2 Family Apoptosis	Cancer
(-)-Mcl-1 inhibitor 22 (compound 38) is an *Mcl-1* inhibitor that works by blocking the interaction between *Mcl-1* and pro-apoptotic proteins, reducing the anti-apoptotic activity of *Mcl-1. (-)-Mcl-1* inhibitor 22 can be used in cancer research .

HY-148899

Mcl-1 inhibitor 10	Bcl-2 Family	Cancer
Mcl-1 inhibitor 10 (compound 43) is a relatively strong *MCL-1* inhibitor (IC₅₀=0.67 μM). Mcl-1 inhibitor 10 interacts with specific binding sites of *MCL-1* protein to block the pro-survival signal of *MCL-1* and push cancer cells into apoptosis. Mcl-1 inhibitor 10 can be used in the study of *MCL-1* dependent cancers .

HY-130261

Mcl-1 antagonist 1	Bcl-2 Family	Cancer
Mcl-1 antagonist 1 is a *Mcl-1* protein antagonist extracted from patent WO2019173181, compound 200 .

HY-170763

Mcl-1 inhibitor 22	Apoptosis Bcl-2 Family	Cancer
Mcl-1 inhibitor 22 (Example 36) is a myeloid cell leukemia-1 (MCL-1) inhibitor which inhibits the antiapoptotoic activity of MCL-1 by inhibiting its interaction with proapototic proteins. Mcl-1 inhibitor 22 exhibits anti-proliferation activities against various cancer cell lines and can be utilized in cancer research .

HY-170763A

(+)-Mcl-1 inhibitor 22	Apoptosis Bcl-2 Family	Cancer
(+)-Mcl-1 inhibitor 22 (Example 37) is a myeloid cell leukemia-1 (MCL-1) inhibitor which inhibits the antiapoptotoic activity of MCL-1 by inhibiting its interaction with proapototic proteins. (+)-Mcl-1 inhibitor 22 exhibits anti-proliferation activities against various cancer cell lines and can be utilized in cancer research .

HY-164453

A-1248767	Bcl-2 Family Apoptosis	Cancer
A-1248767 is a *MCL-1* inhibitor (IC₅₀=23.9 nM; K_i=0.41 nM) with anticancer activity. A-1248767, a derivative of A-1210477 (HY-12468), binds to *MCL-1* with high affinity, induces the increase of intracellular *MCL-1* protein, and promotes tumor cell apoptosis .

HY-125908

A-1210477-piperazinyl PROTAC Mcl1-binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology .

HY-15464

(R)-(-)-Gossypol 2 Publications Verification AT-101; R-(-)-gossypol acetic acid	Bcl-2 Family Autophagy	Cancer
(R)-(-)-Gossypol (AT-101) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to Bcl-2, *Mcl-1* and Bcl-xL proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.

HY-115529

(-)BI97D6	Bcl-2 Family Apoptosis	Cancer
(-)BI97D6 is a broad-spectrum inhibitor of the Bcl-2 protein family, inhibiting *Mcl-1, Bcl-2, Bcl-xL* and Bcl-1 with IC₅₀ values of 0.025, 0.031, 0.076 and 0.122 μM, respectively. (-)BI97D6 stimulates cell death through the Bak and Bax mediated mitochondrial apoptosis pathway. In addition, (-)BI97D6 inhibits *Mcl-1* and can effectively induce apoptosis in acute myeloid leukemia (AML) cells .

HY-160438B

PBX-7011 TFA	Bcl-2 Family Survivin	Cancer
PBX-7011 TFA is a derivative of camptothecin (HY-16560), which inhibits expressions of the cancer related survival genes DDX5, Survivin, Mcl-1 and XIAP in cells FaDu, degrades DDX5 proteins and exhibits anticancer activity .

HY-15464A

(R)-(-)-Gossypol acetic acid 4 Publications Verification AT-101 (acetic acid); (-)-Gossypol acetic acid; (R)-Gossypol acetic acid	Bcl-2 Family Autophagy	Cancer
(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to Bcl-2, *Mcl-1* and Bcl-xL proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.

HY-120113

SC-2001	Apoptosis Bcl-2 Family STAT	Others
SC-2001 is a compound structurally related to obatoclax that has better antitumor effects than obatoclax in liver cancer cell lines, downregulating Mcl-1 protein levels, inhibiting STAT3 phosphorylation, inducing apoptosis, and enhancing SHP1 expression and activity.

HY-119009

TM-233	JAK STAT NF-κB Bcl-2 Family	Cancer
TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein *Mcl-1* by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the *Mcl-1* gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma .

HY-19551

Apogossypolone ApoG2	Bcl-2 Family Apoptosis Autophagy Fungal ROS Kinase	Infection Cancer
Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with K_i values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-X_L, respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy . Apogossypolone also has antifungal activity .

HY-176142

YX0798	CDK c-Myc Apoptosis Bcl-2 Family	Cancer
YX0798 is a selective and orally active CDK9 inhibitor (K_d: 0.28 nM). YX0798 downregulates the oncoprotein c-MYC and pro-survival protein *MCL-1. YX0798 disrupts the cell cycle and results in transcriptomic reprogramming, eventually leading to cell apoptosis*. YX0798 has antitumor activity .

HY-P2343

BH3 hydrochloride	Apoptosis	Cancer
BH3 hydrochloride, a BBB penetrated peptide, provoke apoptosis either by direct activation of pro-apoptotic Bax/Bak or by neutralizing anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A-1) via their BH3 domian .

HY-118341

Clitocine	Apoptosis Bcl-2 Family	Cancer
Clitocine, an adenosine nucleoside analog isolated from mushroom, is a potent and efficacious readthrough agent. Clitocine acts as a suppressor of nonsense mutations and can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles. Clitocine can induce apoptosis in multidrug-resistant human cancer cells by targeting Mcl-1. Anticancer activity .

HY-111537

rel-AZ5576	c-Myc CDK Bcl-2 Family	Others
rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.

HY-146097

RMS5	P-glycoprotein Apoptosis	Cancer
RMS5, a tetrandrine analogue, is a potent P-glycoprotein (P-gp) inhibitor. RMS5 has markedly antiproliferative and cytotoxic effects on cancer cells. RMS5 slightly diminishes the expression of the anti-apoptotic Bcl-2 family proteins Bcl-XL and Mcl-1. RMS3 causes PARP cleavage, a marker for cells undergoing apoptosis. RMS5 has strong anticancer property .

HY-15163A

Zotiraciclib hydrochloride	FLT3 JAK CDK	Cancer
Zotiraciclib hydrochloride is a novel small molecule multi-target enzyme inhibitor with activity in inhibiting tumor growth. Zotiraciclib hydrochloride exerts its anti-tumor effect by reducing the level of Myc through inhibiting cyclin-dependent kinase 9 (CDK9). Zotiraciclib hydrochloride may be useful for inhibiting cancers that cross the blood-brain barrier. The high protein level of MCL-1 of Zotiraciclib hydrochloride is associated with survival, suggesting that it may serve as a prognostic factor and inhibitory target in further studies .

HY-164468

Ch282-5	Bcl-2 Family Apoptosis Autophagy	Cancer
Ch282-5 is an orally active inhibitor targeting the Bcl-2 protein, inducing mitochondria-dependent apoptosis (Apoptosis) by disrupting mitophagy and the mTOR pathway. Ch282-5 exhibits antiproliferative activity against colorectal cancer cells both in vitro and in vivo, and it also inhibits metastasis. Additionally, Ch282-5 enhances Oxaliplatin (HY-17371)-induced autophagy (Autophagy) by downregulating the Mcl-1 protein and increasing platelet count, alleviating adverse effects of Navitoclax (HY-10087) .

HY-169797

STAT3-IN-38	STAT Survivin Apoptosis	Cancer
STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (K_D of rhSTAT3: 45.33 µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and *Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis* in colorectal cancer cells .

HY-N0763

Angelicin Maximum Cited Publications 8 Publications Verification Isopsoralen	Apoptosis Virus Protease NF-κB p38 MAPK JNK Caspase	Infection Inflammation/Immunology Cancer
Angelicin is a furanocoumarin compound that functions as an inhibitor of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory, antiviral, and antitumor activities. It suppresses the lytic replication of γ-herpesviruses, such as MHV-68, early during viral infection, potentially inhibiting RTA gene expression (IC₅₀=28.95 μM). Angelicin also mitigates inflammation by inhibiting the phosphorylation and nuclear translocation of NF-κB, and the phosphorylation of p38 and JNK. Furthermore, it induces apoptosis in neuroblastoma cells by downregulating anti-apoptotic proteins like Bcl-2, Bcl-xL, and *Mcl-1, while activating caspase-9* and caspase-3.

HY-171334A

P1D-34	PROTACs PIN1 CDK Akt c-Myc Apoptosis Reactive Oxygen Species (ROS)	Cancer
P1D-34 is a Pin1 PROTAC degrader with a DC₅₀ value of 177 nM. P1D-34 also down-regulates Pin1 client proteins such as Cyclin D1, Rb, Mcl-1, Akt, and c-Myc. P1D-34 shows anti-proliferative activities in a panel of acute myeloid leukemia (AML) cell lines. P1D-34 induces cell DNA damage and apoptosis by releasing ROS generation. Pink: PIN1 ligand (HY-171442A), Blue: CRBN ligand (HY-14658), Black: Linker (HY-W014883) .

HY-13559

Atiprimod Azaspirane	Apoptosis	Cancer
Atiprimod (Azaspirane) is an orally bioavailable small molecule with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Atiprimod also downregulates the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB transcription factors .

HY-W040129

Chromomycin A3 1 Publications Verification	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase	Infection Neurological Disease Cancer
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-162619

CDK9-IN-33	Apoptosis CDK	Cancer
CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC₅₀ values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .

HY-15191B

(S)-Sabutoclax (S)-BI-97C1	Bcl-2 Family	Cancer
(S)-Sabutoclax ((S)-BI-97C1), an optically pure apogossypol derivative, is pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. (S)-Sabutoclax (Compound II) inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC₅₀ values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. (S)-Sabutoclax also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC₅₀ values of 0.13, 0.56, and 0.049 μM, respectively. (S)-Sabutoclax can be used for the research of apoptosis-based therapies against cancer .

HY-W040129R

Chromomycin A3 (Standard)	Bacterial Fungal Apoptosis Antibiotic	Infection Neurological Disease Cancer
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-N8146

Bruceantinol	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK	Infection Cancer
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of *MCL-1, PTTG1, survivin* and c-Myc. Bruceantinol binds with CDK2/4/6 to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .

HY-153803

GBD-9	PROTACs Molecular Glues Btk	Cancer
GBD-9 is a degrader based on the E3 ubiquitin ligase CRBN that targets BTK and the G1 to S phase transition protein GSPT1. GBD-9 has both PROTAC and molecular glue properties by inducing ubiquitination and proteasomal degradation of target proteins. GBD-9 can efficiently degrade wild-type and mutant BTK (such as C481S mutation) and GSPT1. GBD-9 significantly inhibits tumor cell proliferation by inducing G1 phase arrest in cancer cells, downregulating anti-apoptotic proteins (BCL-2, *MCL-1) and activating Caspase-3* to induce apoptosis. GBD-9 is mainly used in the research of hematological tumors such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) . GBD-9 is composed of E3 ubiquitin ligase ligand (pink part) 5-Aminothalidomide (HY-W023573), target protein ligand (blue part) Btk Inhibitor: IBT6A (HY-13036A), and PROTAC linker (black part) Nonanoic acid (HY-N7057).

HY-164466

CAD204520	Calcium Channel Notch	Cancer
CAD204520, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL) .

Cat. No.	Product Name	Target	Research Area